COMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review.
Level 5 - mechanism / opinion, no new human data
Critical narrative review synthesizing 25 studies without quantitative meta-analysis
PubMed 27241058 · doi:10.1038/tpj.2016.43
What was done
The authors reviewed 25 studies investigating whether the catechol-O-methyltransferase (COMT) val158met single nucleotide polymorphism (rs4680)—which alters cortical dopamine tone—moderates the cognitive effects of dopaminergic medications (including stimulants, COMT inhibitors, and antipsychotics) on prefrontal cortex-dependent cognitive functions such as working memory, selective attention, and executive function.
What was found
Across the 25 reviewed studies, evidence for COMT val158met moderation of cognitive drug effects was mixed for stimulants and COMT inhibitors (drugs with greater relative effects on D1 receptors), but strong for antipsychotic medications (which act predominantly on D2 receptors). The abstract reports no quantitative effect sizes, confidence intervals, or statistical test values.
Why it matters
This review organizes clinical pharmacogenetic evidence around prefrontal dopamine's inverted-U model, highlighting that COMT genotype may help predict individualized cognitive responses to specific classes of dopaminergic agents, particularly antipsychotics.
Limits
The abstract lacks specific search criteria, study quality ratings, quantitative meta-analytic pooling, and numerical effect sizes. Variations in specific cognitive tasks, drug dosages, and participant populations across the 25 included studies are not detailed.
Cited by
- supports Cognitive enhancement from stimulants follows an inverted U-shaped curve where individuals with low baseline performance may experience slight gains, while high-performing individuals risk cognitive impairment.